PARP inhibitors for ovarian cancer survival
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial looks at how well PARP inhibitors (a type of targeted therapy) work for women with ovarian cancer. It includes women newly diagnosed with advanced cancer or those whose cancer came back after a long break from platinum chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with advanced (stage IIIC or IV) ovarian, fallopian tube, or primary peritoneal cancer between December 2013 and December 2024.
- You have complete records of your first treatment and any maintenance therapy after that.
- Or, if you had a recurrence, it was at least 6 months after your last platinum-based chemo (platinum-sensitive).
- Your tumor type is epithelial (not borderline, clear cell, or mucinous carcinoma).
- You have follow-up data available (doctor visits, scans, etc.).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, EZH2 inhibitor and PARP inhibitor, for people with advanced or recurrent epithelial ovarian cancer that does not have BRCA1/2 gene mutations. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests if adding a drug called a PARP inhibitor (which helps block cancer cells from repairing themselves) to standard chemotherapy and heated chemotherapy during surgery (HIPEC) can work better together for ovarian cancer that has already been treated with initial chemo. It is for people with a specific type of advanced ovarian cancer who are planning surgery after chemo.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
Hear when a new PARP Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.